Simulations Plus Reports Third Quarter FY2015 Financial Results

LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. About Cytoxan (Cyclophosphamide) with no Rx (NASDAQ: SLP), the premier provider of simulation and modeling software and consulting services for all phases of pharmaceutical discovery and development from the earliest discovery through all phases of clinical trials, today reported financial results for its third quarter of fiscal year 2015 ended May 31, 2015 (3QFY15), and first nine months of fiscal year 2015 (9moFY15), compared to the third quarter (3QFY14) and first nine months of fiscal year 2014 (9moFY14). 3QFY15 highlights compared with 3QFY14: Net revenues increased 58.9% to $5.94 million, an increase of $2.20 million from $3.74 million Gross profit was up 37.4% to $4.83 million, an increase of $1.31 million from $3.51 million SG&A was $1.62 million, an increase of 34.9% or $420,000 from $1.20 million R&D expenditures were $594,000, an increase of $42,000 or 7.6% over $552,000 In 3QFY15, $246,000 was capitalized and $348,000 was expensed In 3QFY14, $317,000 was capitalized and $235,000 was expensed Income before taxes increased 35.1% to $2.82 million, an increase of $733,000 from $2.09 million Net income increased 41.7% to $1.85 million, an increase of $545,000 from $1.31 million Diluted earnings per share increased 36.5% to $0.108 from $0.079 9moFY15 highlights compared with 9moFY14: Net revenues increased 54.3% to $14.60 million, an increase of $5.14 million from $9.46 million Gross profit was up 37.0% to $11.36 million, an increase of $3.07 million from $8.29 million SG&A was $5.30 million, an increase of $1.92 million or 57.0% from $3.38 million R&D expenditures were $1.96 million, an increase of $154,000, or 8.5% over $1.8 million For 9moFY15, $976,000 was capitalized and $982,000 was expensed For 9moFY14, $1.05 million was capitalized and $751,000 was expensed Income before taxes increased 18.6% to $5.01 million, an increase of $788,000 from $4.23 million Net income increased 19.6% to $3.35 million, an increase of $549,000 from $2.80 million Diluted earnings per share increased 14.6% to $0.196 from $0.171 Mr. Seromycin (Cycloserine) John Kneisel, chief financial officer of Simulations Plus, said: “The Company delivered record results aided by a strong quarter of software sales and consulting revenues. Zero Nicotine () without Rx Year-to-date diluted earnings per share reached the 20c mark. Buy Cytodrox with free prescription After distributing just over $800,000 in dividends during 3QFY15, cash on May 31 was a healthy $6.4 million and is currently at $7.8 million.” Ted Grasela, president of Simulations Plus and its wholly owned subsidiary, Cognigen Corporation, added: “Strong collaborations between our scientists have identified new and innovative ways of using modeling and simulation to bring valuable insights to our clients’ research and development programs. Anaprox (Naproxen) with no Rx The strategic and synergistic benefits of the Cognigen acquisition are being realized and we look forward to finding even more synergies between the talent and technologies of the two Simulations Plus divisions.” Walt Woltosz, chairman and CEO of Simulations Plus and Cognigen, added: “We believe the combined Simulations Plus/Cognigen team, which now spans all aspects of drug development from early discovery chemistry through clinical trials and on to generics, provides the most comprehensive offering of powerful software and consulting expertise available to the pharmaceutical industry today. Buy Protein Bars online We’re realizing the potential we expected from joining the predominantly preclinical and early clinical capabilities of Simulations Plus with the world-class clinical trial data analysis and reporting expertise of Cognigen, with a number of projects now using the expertise from both teams to meet customers’ needs. http://webmdhelper.wordpress.com Scientists from both divisions are learning about the methods used by each other, which will enable them to communicate the advantages of working with our organization as they go out to scientific meetings and conferences, and to provide training at customer sites. We believe this is just the beginning, as more and more managers in drug development are recognizing the tremendous potential of model-based drug development through best-in-class software and top-notch consulting expertise.” Dividend Announcement The Company today announced that its board of directors has declared a quarterly cash dividend of $0.05 per share to its shareholders. This cash dividend will be distributed on Thursday, July 30, 2015, for shareholders of record as of Thursday, July 23, 2015. Investor Conference Call The Company will hold an investor conference call on Monday, July 13, at 1:15 p.m. PT/4:15 p.m. ET. The conference call will be webcast live and may be joined by registering at: attendee.gotowebinar.com/register/7514990819733113602. After registering, you will receive a confirmation email containing information about joining the webinar. Please dial in five to ten minutes prior to the scheduled start time. For listen-only mode, you may dial (415) 655-0059, and enter access code 307-841-003. About Simulations Plus, Inc. and Cognigen Corp. Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation and modeling software which is licensed to and used in the conduct of drug research by major pharmaceutical, biotechnology, agrochemical, and food industry companies worldwide. Simulations Plus recently acquired Cognigen Corporation of Buffalo, NY, adding to our offerings top-quality statistical modeling and simulation using clinical trial data, as well as more than doubling our staff from 30 to over 60, adding nearly 50% to revenues, and increasing earnings in the fiscal year that began September 1, 2014. The Company is headquartered in Southern California and trades on the NASDAQ Capital Market under the symbol “SLP.” Cognigen Corp. is located in Buffalo, New York. For more information, visit our Web site at .simulations-plus.com. Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with the U.S. Securities and Exchange Commission. --Tables follow -- SIMULATIONS PLUS, INC. CONDENSED CONSOLIDATED BALANCE SHEETS As of   (Unaudited)   (Audited) May 31,   August 31, ASSETS 2015 2014 Current assets Cash and cash equivalents $ 6,428,596 $ 8,614,929 Accounts receivable, net of allowance for doubtful accounts of $0 3,990,467 1,708,158 Revenues in excess of billings 924,793 158,914 Prepaid income taxes - 748,359 Prepaid expenses and other current assets 269,776 188,160 Deferred income taxes   209,705   114,846 Total current assets $ 11,823,337 $ 11,533,366 Long-term assets Capitalized computer software development costs, net of accumulated amortization of $7,358,012 and $6,609,283 $ 3,880,162 $ 3,452,541 Property and equipment, net 420,629 95,242 Intellectual property, net of accumulated amortization of $649,375 and $193,750 5,425,625 5,881,250 Other intangible assets net of accumulated amortization of $110,625 1,539,375 - Goodwill 4,789,248 - Other assets   34,082   18,445 Total assets $ 27,912,458 $ 20,980,844   LIABILITIES AND SHAREHOLDERS EQUITY Current liabilities Accounts payable $ 133,126 $ 130,547 Accrued payroll and other expenses 427,750 340,709 Accrued bonuses to officer 72,000 120,000 Income taxes payable 178,894 - Other current liabilities 19,859 19,859 Current portion - Contracts payable 750,000 750,000 Billings in excess of revenues 93,122 - Deferred revenue   42,168   30,370 Total current liabilities $ 1,716,919 $ 1,391,485   Long-term liabilities Deferred income taxes $ 3,510,899 $ 2,375,874 Payments due under Contracts payable 2,854,404 1,750,000 Other long-term liabilities   13,239   28,134 Total liabilities $ 8,095,461 $ 5,545,493   Commitments and contingencies   Shareholders equity Preferred stock, $0.001 par value 10,000,000 shares authorized no shares issued and outstanding $ - $ - Common stock, $0.001 par value 50,000,000 shares authorized 16,887,117 and 16,349,955 shares issued and outstanding $ 5,358 $ 4,821 Additional paid-in capital 9,643,394 6,085,427 Retained earnings   10,168,245   9,345,103 Total shareholders equity $ 19,816,997 $ 15,435,351 Total liabilities and shareholders equity $ 27,912,458 $ 20,980,844   SIMULATIONS PLUS, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS For the three and nine months ended May 31, (Unaudited)   Three months ended   Nine months ended 2015   2014 2015   2014   Net Revenues $ 5,942,082 $ 3,740,567 $ 14,602,464 $ 9,463,059 Cost of revenues $ 1,115,402     227,600     3,238,796     1,168,219   Gross margin $ 4,826,680     3,512,967     11,363,668     8,294,840   Operating expenses Selling, general, and administrative $ 1,624,610 1,204,312 5,303,792 3,378,950 Research and development $ 348,285     234,685     981,633     750,808   Total operating expenses $ 1,972,895     1,438,997     6,285,425     4,129,758     Income from operations $ 2,853,785     2,073,970     5,078,243     4,165,082     Other income (expense) Interest income $ 4,391 8,017 13,394 25,000 Gain (loss) on currency exchange $ (35,632 )   7,340     (78,107 )   35,477   Total other income (expense) $ (31,241 )   15,357     (64,713 )   60,477   Income from operations before provision for income taxes $ 2,822,544 2,089,327 5,013,530 4,225,559 Provision for income taxes $ (970,122 )   (781,778 )   (1,661,972 )   (1,422,991 ) Net Income $ 1,852,422   $ 1,307,549   $ 3,351,558   $ 2,802,568     Earnings per share Basic $ 0.11 $ 0.08 $ 0.20 $ 0.17 Diluted $ 0.11 $ 0.08 $ 0.20 $ 0.17   Weighted-average common shares outstanding Basic 16,862,128 16,193,976 16,847,191 16,117,198 Diluted 17,073,155 16,455,078 17,070,334 16,361,695